Autres langues NLS PHARPAR

Actions

NLSP

CH1384053976

Temps Différé Nasdaq 17:23:45 17/08/2026			Varia. 5j.	Varia. 1 janv.
3,260 ^USD	-2,54%		+1,06%	-57,22%

30/10/25	NLS Pharmaceutics Ltd. et Kadimastem Ltd. annoncent la finalisation de leur fusion	RE
30/10/25	NLS Pharmaceutics Ltd. et Aexon Labs annoncent l'extension de leur plateforme DOXA avec la série AEX-6xx	CI

Autres langues

17/11	NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute
30/10/25	NLS Pharmaceutics Ltd. and Kadimastem Ltd. announce completion of merger
30/10/25	NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger
30/10/25	NLS Pharmaceutics Ltd. and Aexon Labs Announces the Expansion of Their Doxa Platform with the AEX-6xx Series
30/10/25	NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs
30/10/25	NLS Pharmaceutics AG(NasdaqCM:NLSP) dropped from NASDAQ Composite Index
30/10/25	Kadimastem Ltd completed the acqusiition of NLS Pharmaceutics AG from Magnetic Rock Investment AG, BVF Partners L.P., Lind Global Fund II LP a fund managed by The Lind Partners, LLC, YA II PN, Ltd. a managed by Yorkville Advisors Global LP, Felix Grisard, Ronald Hafner and others in a reverse merger transaction.
29/10/25	NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger
29/10/25	Ronen Twito to Become CEO of NewCelX
29/10/25	Ronen Twito to Become Executive Chairman of NewCelX
29/10/25	Nls pharmaceutics announces 1-for-10 reverse share split and name change in connection with proposed merger with Kadimastem
06/10/25	NLS Pharmaceutics AG Reports Earnings Results for the Half Year Ended June 30, 2025
30/09/25	NLS Pharmaceutics shareholders approve merger with Kadimastem and related proposals at extraordinary general meeting
10/09/25	Kadimastem, NLS Pharmaceutics announce effectiveness of SEC registration statement for proposed merger
01/09/25	Swiss stocks - Factors to watch on September 1
29/08/25	NLS Pharmaceutics AG agreed to extend merger agreement termination date with Kadimastem from Aug 31 to Oct 31
17/07/25	Bird Foundation Approves Additional Milestone Payment to Kadimastem and Itolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy
26/06/25	NLS Pharmaceutics AG announced that it has received $3.000002 million in funding from The Hewlett Fund LP, Rainforest Partners LLC, Alpha Capital Anstalt
17/06/25	NLS Pharmaceutics AG announced that it expects to receive $25 million in funding
22/05/25	NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting
21/05/25	NLS Pharmaceutics Ltd. to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting
16/05/25	NLS Pharmaceutics AG Reports Earnings Results for the Full Year Ended December 31, 2024
24/04/25	NLS Pharmaceutics Ag Announces Resignation of Audrey Greenberg from the Board of Directors, Effective April 18, 2025
15/04/25	NLS Pharmaceutics Study Suggests Mazindol May Help Treat Fentanyl Use Disorder
15/04/25	Nls Pharmaceutics Announces Positive Results From Study Ko-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward In Animal Models